Literature DB >> 17412303

Animal models for autoimmune hepatitis.

Urs Christen1, Martin Holdener, Edith Hintermann.   

Abstract

The liver is the target of adverse immune reactions in three putative autoimmune diseases: autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). These three diseases can be distinguished by clinical, histological, and immunological features. However, especially on the level of specific antibody formation an overlap can occur, which sometimes complicates diagnosis. In this review, we will concentrate on autoimmune hepatitis and the current state of animal models for this severe disease. AIH is characterized by the presence of interface hepatitis and portal plasma cell infiltration, hypergammaglobulinemia, and autoantibodies. The hallmark of type 2 AIH is the generation of autoantibodies of the LKM-1 type. The major target of these antibodies is the cytochrome P450 isoform 2D6 (CYP2D6). In the past several attempts have been made to develop a reliable animal model that reflects the persistent hepatic destruction that occurs in human AIH. However, most models were only successful in causing a transient form of hepatic damage and often used rather complex ways of disease induction.

Entities:  

Mesh:

Year:  2006        PMID: 17412303     DOI: 10.1016/j.autrev.2006.04.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  12 in total

Review 1.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

2.  Generation of a cholangiocyte-specific cDNA expression library for the identification of B and T cell autoantigens in murine biliary disease.

Authors:  Rebecca M Tucker; Cara L Mack
Journal:  Hepatol Res       Date:  2012-01-11       Impact factor: 4.288

Review 3.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

4.  Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis.

Authors:  Yves Renaudineau; Geogios N Dalekos; Paul Guéguen; Kalliopi Zachou; Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

5.  Development of a spontaneous liver disease resembling autoimmune hepatitis in mice lacking tyro3, axl and mer receptor tyrosine kinases.

Authors:  Nan Qi; Peipei Liu; Yue Zhang; Hui Wu; Yongmei Chen; Daishu Han
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

6.  The CYP2D6 animal model: how to induce autoimmune hepatitis in mice.

Authors:  Edith Hintermann; Janine Ehser; Urs Christen
Journal:  J Vis Exp       Date:  2012-02-03       Impact factor: 1.355

Review 7.  The Pharmacological Targets and Clinical Evidence of Natural Products With Anti-hepatic Inflammatory Properties.

Authors:  Jinghua Peng
Journal:  Front Pharmacol       Date:  2018-06-05       Impact factor: 5.810

8.  Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview.

Authors:  Hind I Fallatah; Hisham O Akbar
Journal:  Autoimmune Dis       Date:  2012-12-12

9.  Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis.

Authors:  Fan Lian; Yu Wang; Youjun Xiao; Xiwen Wu; Hanshi Xu; Liuqin Liang; Xiuyan Yang
Journal:  Mol Med Rep       Date:  2015-07-31       Impact factor: 2.952

10.  Complementary serum proteomic analysis of autoimmune hepatitis in mice and patients.

Authors:  Hongbin Li; Guoshun Li; Xinyu Zhao; Yongkang Wu; Wen Ma; Yuling Liu; Fengming Gong; Shufang Liang
Journal:  J Transl Med       Date:  2013-06-13       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.